TMCnet News
Elixir Medical Announces Schedule of Programs for TCT 2016Elixir Medical Corporation, a developer of products that combine state-of-the-art medical devices with advanced pharmaceuticals, announced that it will showcase the first live case demonstration by transmission in the USA of its breakthrough DESolve® NXT Novolimus Eluting Bioresorbable Coronary Scaffold System at the 28th annual Transcatheter Cardiovascular Technologies (TCT) Conference in Washington, DC on Sunday, October 30. The Elixir-sponsored symposium is also scheduled for Sunday, October 30th from 6-8 PM. Elixir will announce new six-month data for its 120µm thin-strut DESolve Cx Fully Bioresorbable Novolimus Eluting Coronary Scaffold System and the four-year data on the DESolve Novolimus eluting scaffold during the scientific conference. Following are the details of Elixir Medical's programs and activities at TCT in Eastern Standard Time (EST): Saturday, October 29:
6:00 - 8:00 PM, Washington Convention Center Hall B, Lower Level Sunday, October 30:
10:30 AM, Washington Convention Center, Main Arena Sunday, October 30:
6 - 8 PM, Marriott Marquis Ballroom, Salon 6, Level M2 Chairs
Panelist Faculty
Space is limited: Please register in advance at http://www.crf.org/tct/agenda/satellite-programs Monday, October 31: Device Specifications and Clinical Program Update
10:34 AM, Washington Convention Center, Room 305, Level 3
12:45 PM, Washington Convention Center, Room 103B, Level 1
4:22 PM, Washington Convention Center Room 151, Level 1 Tuesday, November 1:
10:14 AM, Washington Convention Center Room 103B, Level 1
2:00 PM, Washington Convention Center Room 207, Level 2
7:22 PM, Marriott Marquis, Salon 1-4, Level M2 Elixir Medical will have a booth at TCT: Booth 1309, Exhibit Hall. The booth will be open Sunday, October 30 and Monday, October 31 from 9 am to 5 pm, and Tuesday, November 1 from 9 am to 2 pm. About Elixir Medical Elixir Medical Corporation, a privately held company headquartered in Sunnyvale, California, develops products that combine state-of-the-art medical devices with advanced pharmaceuticals to provide innovative treatment solutions to patients worldwide. The company's next-generation drug-eluting stent systems and bioresorbable coronary scaffold are designed to optimize localized drug delivery to provide safe and effective treatments for cardiovascular patients. For more information, visit www.elixirmedical.com. View source version on businesswire.com: http://www.businesswire.com/news/home/20161019005484/en/ |